Centauri Therapeutics raises £6m from AMR Action Fund to extend Series A round to £30m
The funding will support Phase I clinical trials for the company lead antimicrobial candidate.
A British biotechnology firm developing immunotherapies to combat drug-resistant bacterial infections using its proprietary Alphamer platform.
Centauri Therapeutics has secured £6m from the AMR Action Fund, bringing the total value of its extended Series A funding round to £30m. The capital will be deployed to advance CTX-187, the lead clinical candidate in the company ABX-01 programme, through Phase I clinical trials and prepare it for subsequent Phase II development.
The fresh injection of funds supports the completion of Phase I studies to generate essential safety data for the asset. The company aims to leverage this backing to position CTX-187 for advanced clinical evaluation.
This extension follows earlier funding milestones, including a £24m initial Series A close in January 2022 supported by Boehringer Ingelheim Venture Fund, Evotec SE, and Novo Holdings REPAIR Impact Fund. The Alphamer platform combines immunotherapeutic effects with direct antibacterial activity to tackle pressing unmet medical needs in infectious disease.
From the founder
"We are extremely pleased to welcome the AMR Action Fund as a new investor. Their dedication to advancing the field of antimicrobials further reinforces our belief in the Alphamer platform as a transformative immunotherapeutic approach for addressing infections. This latest investment has enabled us a clear path to progress CTX-187 beyond Phase I trials and onto the development of a Phase II-ready asset. I would like to thank the AMR Action Fund, as well as all of our existing investors and collaborators, for their support."
Jennifer Schneider
Chief Executive Officer at Centauri Therapeutics
Use of funds
- 01Fund research and development
Investors
Categories
About the company
Centauri Therapeutics
Centauri Therapeutics develops novel immunotherapies to target multidrug-resistant Gram-negative bacteria.